The advent of amyloid-β (Aβ) and tau PET imaging has revolutionized Alzheimer disease (AD) research, enabling in vivo ...

Radiotheranostics refers to dual diagnostic–therapeutic capacity that allows for precision medicine at an unprecedented level, reducing collateral toxicity and improving patient outcomes ([1][1]). In ...

Journal of Nuclear Medicine September 2025, jnumed.125.269636; DOI: https://doi.org/10.2967/jnumed.125.269636 ...

Journal of Nuclear Medicine September 2025, jnumed.125.270358; DOI: https://doi.org/10.2967/jnumed.125.270358 ...

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. After the use of liver-directed therapies, it is challenging to differentiate between nonviable tumor and ...

Journal of Nuclear Medicine August 2025, jnumed.124.269234; DOI: https://doi.org/10.2967/jnumed.124.269234 ...

Journal of Nuclear Medicine July 2025, jnumed.125.270167; DOI: https://doi.org/10.2967/jnumed.125.270167 ...

Journal of Nuclear Medicine July 2025, jnumed.125.269729; DOI: https://doi.org/10.2967/jnumed.125.269729 ...

Radioimmunotherapy using 225Ac, a highly cytotoxic α-particle emitter, has potential for treating advanced breast cancer, especially human epidermal growth factor receptor 2 (HER2)–positive cases. We ...

Results: The patients underwent 1-2 cycles of TANDEM PRLT with 177 Lu (5.05 ± 1.09 GBq) and 225 Ac (6.87 ± 3.14 MBq) per cycle, receiving 16 BTX treatments. All patients were heavily pre-treated, with ...

Journal of Nuclear Medicine June 2025, 66 (supplement 1) 252173; ...

Journal of Nuclear Medicine May 2025, jnumed.125.269519; DOI: https://doi.org/10.2967/jnumed.125.269519 ...